Neoplastic Precursor Lesions Related to the Development of Cancer in Inflammatory Bowel Disease

Gastroenterology Clinics of North America

Volumn 36, Issue 4, 2007, Pages 901-926

  Harpaz, Noam ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CARCINOGENESIS; COLON RESECTION; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DYSPLASIA; ENDOSCOPIC POLYPECTOMY; ENTERITIS; HEALTH CARE PERSONNEL; HEALTH SURVEY; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; MOLECULAR BIOLOGY; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW;

COLORECTAL NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES; PRECANCEROUS CONDITIONS; PROGNOSIS; RISK FACTORS;

EID: 35748966145     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2007.08.003     Document Type: Review

References (117)

1. Eaden J.A., Abrams K.R., and Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48 4 (2001) 526-535
2. Eaden J.A., and Mayberry J.F. Colorectal cancer complicating ulcerative colitis: a review. Am J Gastroenterol 95 10 (2000) 2710-2719
3. Gyde S.N., Prior P., Thompson H., et al. Survival of patients with colorectal cancer complicating ulcerative colitis. Gut 25 3 (1984) 228-231
4. Harpaz N., and Talbot I.C. Colorectal cancer in idiopathic inflammatory bowel disease. Semin Diagn Pathol 13 4 (1996) 339-357
5. Itzkowitz S.H., and Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126 6 (2004) 1634-1648
6. Rutter M.D., Saunders B.P., Wilkinson K.H., et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 130 4 (2006) 1030-1038
7. Greenstein A.J., Sachar D.B., Smith H., et al. Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology 77 2 (1979) 290-294
8. Itzkowitz S.H. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am 35 3 (2006) 553-571
9. Croog V.J., Ullman T.A., and Itzkowitz S.H. Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis 18 5 (2003) 392-400
10. Rubin D.T., LoSavio A., Yadron N., et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 4 11 (2006) 1346-1350
11. Ullman T.A. Preventing neoplastic progression in ulcerative colitis. J Clin Gastroenterol 39 4 Suppl 2 (2005) S66-S69
12. Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther 20 Suppl 4 (Oct 2004) 24-30
13. Bernstein C.N., Blanchard J.F., Kliewer E., et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 15 91 4 (2001) 854-862
14. Choi P.M., and Zelig M.P. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 35 7 (1994) 950-954
15. Ekbom A., Helmick C., Zack M., et al. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 336 8711 (1990) 357-359
16. Gillen C.D., Andrews H.A., Prior P., et al. Crohn's disease and colorectal cancer. Gut 35 5 (1994) 651-655
17. Jess T., Gamborg M., Matzen P., et al. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 100 12 (2005) 2724-2729
18. Rutter M., Saunders B., Wilkinson K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126 2 (2004) 451-459
19. Bansal Gupta R., Harpaz N., Itzkowitz S., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133 4 (2007) 1099-1105
20. Jess T., Loftus Jr. E.V., Velayos F.S., et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis 12 8 (2006) 669-676
21. Broome U., Lofberg R., Veress B., et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 22 5 (1995) 1404-1408
22. Aadland E., Schrumpf E., Fausa O., et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 22 6 (1987) 655-664
23. Brentnall T.A., Haggitt R.C., Rabinovitch P.S., et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 110 2 (1996) 331-338
24. Broome U., Lindberg G., and Lofberg R. Primary sclerosing cholangitis in ulcerative colitis-a risk factor for the development of dysplasia and DNA aneuploidy?. Gastroenterology 102 6 (1992) 1877-1880
25. Kornfeld D., Ekbom A., and Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 41 4 (1997) 522-525
26. Shetty K., Rybicki L., Brzezinski A., et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 94 6 (1999) 1643-1649
27. Askling J., Brandt L., Lapidus A., et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 54 5 (2005) 617-622
28. Nuako K.W., Ahlquist D.A., Mahoney D.W., et al. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology 115 5 (1998) 1079-1083
29. Greenstein A.J., Sachar D.B., Smith H., et al. Patterns of neoplasia in Crohn's disease and ulcerative colitis. Cancer 46 2 (1980) 403-407
30. Hamilton S.R. Colorectal carcinoma in patients with Crohn's disease. Gastroenterology 89 2 (1985) 398-407
31. Greenstein A.J., Slater G., Heimann T.M., et al. A comparison of multiple synchronous colorectal cancer in ulcerative colitis, familial polyposis coli, and de novo cancer. Ann Surg 203 2 (1986) 123-128
32. von Herbay A., Herfarth C., and Otto H.F. Cancer and dysplasia in ulcerative colitis: a histologic study of 301 surgical specimen. Z Gastroenterol 32 7 (1994) 382-388
33. Mathy C., Schneider K., Chen Y.Y., et al. Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. Inflamm Bowel Dis 9 6 (2003) 351-355
34. Warren S., and Sommers S.C. Pathogenesis of ulcerative colitis. Am J Pathol 25 (1949) 657-679
35. Morson B.C., and Pang L.S. Rectal biopsy as an aid to cancer control in ulcerative colitis. Gut 8 5 (1967) 423-434
36. Connell W.R., Talbot I.C., Harpaz N., et al. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut 35 10 (1994) 1419-1423
37. Lennard-Jones J.E., Melville D.M., Morson B.C., et al. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut 31 7 (1990) 800-806
38. Ekbom A., Helmick C., Zack M., et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323 18 (1990) 1228-1233
39. Petras R.E., Mir-Madjlessi S.H., and Farmer R.G. Crohn's disease and intestinal carcinoma. A report of 11 cases with emphasis on associated epithelial dysplasia. Gastroenterology 93 6 (1987) 1307-1314
40. Richards M.E., Rickert R.R., and Nance F.C. Crohn's disease-associated carcinoma. A poorly recognized complication of inflammatory bowel disease. Ann Surg 209 6 (1989) 764-773
41. Sigel J.E., Petras R.E., Lashner B.A., et al. Intestinal adenocarcinoma in Crohn's disease: a report of 30 cases with a focus on coexisting dysplasia. Am J Surg Pathol 23 6 (1999) 651-655
42. Stahl T.J., Schoetz Jr. D.J., Roberts P.L., et al. Crohn's disease and carcinoma: increasing justification for surveillance?. Dis Colon Rectum 35 9 (1992) 850-856
43. Thomas T., Abrams K.A., Robinson R.J., et al. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther 25 6 (2007) 657-668
44. Bernstein C.N., Shanahan F., and Weinstein W.M. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. Lancet 343 8889 (1994) 71-74
45. Connell W.R., Lennard-Jones J.E., Williams C.B., et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 107 4 (1994) 934-944
46. Lennard-Jones J.E., Morson B.C., Ritchie J.K., et al. Cancer surveillance in ulcerative colitis. Experience over 15 years. Lancet 2 8342 (1983) 149-152
47. Barthet M., Gay G., Sautereau D., et al. Endoscopic surveillance of chronic inflammatory bowel disease. Endoscopy 37 6 (2005) 597-599
48. Eaden J.A., and Mayberry J.F. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 51 Suppl 5 (2002) V10-V12
49. Itzkowitz S.H., and Present D.H. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 11 3 (2005) 314-321
50. Friedman S., Rubin P.H., Bodian C., et al. Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology 120 4 (2001) 820-826
51. Collins P.D., Mpofu C., Watson A.J., et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2 (2006) CD000279
52. Riddell R.H., Goldman H., Ransohoff D.F., et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14 11 (1983) 931-968
53. Hamilton S.R., and Aaltonen L.A. Pathology and Genetics. Tumours of the Digestive System Vol 2 (2000), IARC, Lyon
54. Schlemper R.J., Riddell R.H., Kato Y., et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 47 2 (2000) 251-255
55. Andersen S.N., Lovig T., Clausen O.P., et al. Villous, hypermucinous mucosa in long standing ulcerative colitis shows high frequency of K-ras mutations. Gut 45 5 (1999) 686-692
56. Antonioli D.A., Covell L.M., and Goldman H. Villous epithelial regeneration and dysplasia in ulcerative colitis. Arch Pathol Lab Med 101 4 (1977) 222-223
57. Rubio C.A., Johansson C., Slezak P., et al. Villous dysplasia. An ominous histologic sign in colitic patients. Dis Colon Rectum 27 5 (1984) 283-287
58. Rubio C.A., Befrits R., Jaramillo E., et al. Villous and serrated adenomatous growth bordering carcinomas in inflammatory bowel disease. Anticancer Res 20 6C (2000) 4761-4764
59. Hyde G.M., Jewell D.P., and Warren B.F. Histological changes associated with the use of intravenous cyclosporin in the treatment of severe ulcerative colitis may mimic dysplasia. Colorectal Dis 4 6 (2002) 455-458
60. Blackstone M.O., Riddell R.H., Rogers B.H., et al. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology 80 2 (1981) 366-374
61. Medlicott S.A., Jewell L.D., Price L., et al. Conservative management of small adenomata in ulcerative colitis. Am J Gastroenterol 92 11 (1997) 2094-2098
62. Engelsgjerd M., Farraye F.A., and Odze R.D. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 117 6 (1999) 1288-1294 [discussion 1488-1291]
63. Odze R.D., Farraye F.A., Hecht J.L., et al. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol 2 7 (2004) 534-541
64. Rubin P.H., Friedman S., Harpaz N., et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 117 6 (1999) 1295-1300
65. Farraye FA, Waye JD, Heeren TC, et al. Variability in the diagnosis and management of adenoma-like and non-adenoma like DALMs in patients with ulcerative colitis. Gastrointest Endosc, in press.
66. Harpaz N. Adenoma-like dysplastic polyps in inflammatory bowel disease. Pathol Case Rev 9 4 (2004) 135-141
67. Friedman S., Odze R.D., and Farraye F.A. Management of neoplastic polyps in inflammatory bowel disease. Inflamm Bowel Dis 9 4 (2003) 260-266
68. Itzkowitz S. Polypoid dysplasia in inflammatory bowel disease: removing the bumps in the road. Inflamm Bowel Dis 12 9 (2006) 919-920
69. Torres C., Antonioli D., and Odze R.D. Polypoid dysplasia and adenomas in inflammatory bowel disease: a clinical, pathologic, and follow-up study of 89 polyps from 59 patients. Am J Surg Pathol 22 3 (1998) 275-284
70. Schneider A., and Stolte M. Differential diagnosis of adenomas and dysplastic lesions in patients with ulcerative colitis. Z Gastroenterol 31 11 (1993) 653-656
71. Cymes K., and Harpaz N. Partial- vs full-thickness mucosal dysplasia in resected colons with ulcerative colitis: implications for distinction between colitis-associated and sporadic (adenomatous) dysplasia. Lab Invest 79 1 (1999) 74A
72. Fogt F., Zhuang Z., Poremba C., et al. Comparison of p53 immunoexpression with allelic loss of p53 in ulcerative colitis-associated dysplasia and carcinoma. Oncol Rep 5 2 (1998) 477-480
73. Odze R.D., Brown C.A., Hartmann C.J., et al. Genetic alterations in chronic ulcerative colitis-associated adenoma-like DALMs are similar to non-colitic sporadic adenomas. Am J Surg Pathol 24 9 (2000) 1209-1216
74. Selaru F.M., Xu Y., Yin J., et al. Artificial neural networks distinguish among subtypes of neoplastic colorectal lesions. Gastroenterology 122 3 (2002) 606-613
75. Walsh S.V., Loda M., Torres C.M., et al. P53 and beta catenin expression in chronic ulcerative colitis-associated polypoid dysplasia and sporadic adenomas: an immunohistochemical study. Am J Surg Pathol 23 8 (1999) 963-969
76. Ullman T. Chromoendoscopy should be the standard method and more widely used for cancer surveillance colonoscopy in ulcerative colitis-con. Inflamm Bowel Dis 13 10 (2007) 1273-1274
77. Rutter M.D., Saunders B.P., Wilkinson K.H., et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc 60 3 (2004) 334-339
78. Rubin D.T., Rothe J.A., Hetzel J.T., et al. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?. Gastrointest Endosc 65 7 (2007) 998-1004
79. Rubin C.E., Haggitt R.C., Burmer G.C., et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103 5 (1992) 1611-1620
80. Obrador A., Ginard D., and Barranco L. Review article: colorectal cancer surveillance in ulcerative colitis-What should we be doing?. Aliment Pharmacol Ther 24 Suppl 3 (2006) 56-63
81. Eaden J.A., Ward B.A., and Mayberry J.F. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc 51 2 (2000) 123-128
82. Ullman T., Croog V., Harpaz N., et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 125 5 (2003) 1311-1319
83. Melville D.M., Richman P.I., Shepherd N.A., et al. Brush cytology of the colon and rectum in ulcerative colitis: an aid to cancer diagnosis. J Clin Pathol 41 11 (1988) 1180-1186
84. Hurlstone D.P., McAlindon M.E., Sanders D.S., et al. Further validation of high-magnification chromoscopic-colonoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 126 1 (2004) 376-378
85. Hurlstone D.P., Sanders D.S., Lobo A.J., et al. Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy 37 12 (2005) 1186-1192
86. Rutter M.D., Saunders B.P., Schofield G., et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 53 2 (2004) 256-260
87. Kiesslich R., Fritsch J., Holtmann M., et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 124 4 (2003) 880-888
88. Kiesslich R., Goetz M., Lammersdorf K., et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology 132 3 (2007) 874-882
89. Befrits R., Ljung T., Jaramillo E., et al. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum 45 5 (2002) 615-620
90. Lim C.H., Dixon M.F., Vail A., et al. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 52 8 (2003) 1127-1132
91. Woolrich A.J., DaSilva M.D., and Korelitz B.I. Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia. Gastroenterology 103 2 (1992) 431-438
92. Nugent F.W., Haggitt R.C., and Gilpin P.A. Cancer surveillance in ulcerative colitis. Gastroenterology 100 5 Pt 1 (1991) 1241-1248
93. Levi G.S., and Harpaz N. Intestinal low-grade tubuloglandular adenocarcinoma in inflammatory bowel disease. Am J Surg Pathol 30 8 (2006) 1022-1029
94. Jani N., Kornbluth A., Croog V., et al. The fate of indefinite dysplasia in ulcerative colitis. Gastroenterology 124 4 Suppl 1 (2003) A649-A650
95. Dixon M.F., Brown L.J., Gilmour H.M., et al. Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology 13 4 (1988) 385-397
96. Dundas S.A., Kay R., Beck S., et al. Can histopathologists reliably assess dysplasia in chronic inflammatory bowel disease?. J Clin Pathol 40 11 (1987) 1282-1286
97. Eaden J., Abrams K., McKay H., et al. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol 194 2 (2001) 152-157
98. Melville D.M., Jass J.R., Morson B.C., et al. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum Pathol 20 10 (1989) 1008-1014
99. Odze R.D., Goldblum J., Noffsinger A., et al. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol 15 4 (2002) 379-386
100. Odze R.D., Tomaszewski J.E., Furth E.E., et al. Variability in the diagnosis of dysplasia in ulcerative colitis by dynamic telepathology. Oncol Rep 16 5 (2006) 1123-1129
101. Karlen P., Young E., Brostrom O., et al. Sialyl-Tn antigen as a marker of colon cancer risk in ulcerative colitis: relation to dysplasia and DNA aneuploidy. Gastroenterology 115 6 (1998) 1395-1404
102. Itzkowitz S.H., Young E., Dubois D., et al. Sialosyl-Tn antigen is prevalent and precedes dysplasia in ulcerative colitis: a retrospective case-control study. Gastroenterology 110 3 (1996) 694-704
103. Fogt F., Poremba C., Shibao K., et al. Expression of survivin, YB-1, and KI-67 in sporadic adenomas and dysplasia-associated lesions or masses in ulcerative colitis. Appl Immunohistochem Mol Morphol 9 2 (2001) 143-149
104. Wong N.A., Mayer N.J., MacKell S., et al. Immunohistochemical assessment of Ki67 and p53 expression assists the diagnosis and grading of ulcerative colitis-related dysplasia. Histopathology 37 2 (2000) 108-114
105. Noffsinger A.E., Miller M.A., Cusi M.V., et al. The pattern of cell proliferation in neoplastic and nonneoplastic lesions of ulcerative colitis. Cancer 78 11 (1996) 2307-2312
106. Azarschab P., Porschen R., Gregor M., et al. Epigenetic control of the E-cadherin gene (CDH1) by CpG methylation in colectomy samples of patients with ulcerative colitis. Genes Chromosomes Cancer 35 2 (2002) 121-126
107. Arai N., Mitomi H., Ohtani Y., et al. Enhanced epithelial cell turnover associated with p53 accumulation and high p21WAF1/CIP1 expression in ulcerative colitis. Mod Pathol 12 6 (1999) 604-611
108. Harpaz N., Peck A.L., Yin J., et al. P53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. Hum Pathol 25 10 (1994) 1069-1074
109. Hussain S.P., Amstad P., Raja K., et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 60 13 (2000) 3333-3337
110. Holzmann K., Klump B., Borchard F., et al. Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis. Int J Cancer 76 1 (1998) 1-6
111. Dorer R., and Odze R.D. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am J Surg Pathol 30 7 (2006) 871-877
112. Schulmann K., Mori Y., Croog V., et al. Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. Gastroenterology 129 1 (2005) 74-85
113. Burmer G.C., Rabinovitch P.S., Haggitt R.C., et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 103 5 (1992) 1602-1610
114. Itzkowitz S.H., and Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287 1 (2004) G7-G17
115. Risques R.A., Rabinovitch P.S., and Brentnall T.A. Cancer surveillance in inflammatory bowel disease: new molecular approaches. Curr Opin Gastroenterol 22 4 (2006) 382-390
116. Chen R., Rabinovitch P.S., Crispin D.A., et al. DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am J Pathol 162 2 (2003) 665-672
117. Chen R., Rabinovitch P.S., Crispin D.A., et al. The initiation of colon cancer in a chronic inflammatory setting. Carcinogenesis 26 9 (2005) 1513-1519